FDA approves avapritinib (Ayvakit) for treatment of adults with unresectable or metastatic gastrointestinal stromal tumour

Source:
US Food and Drug Administration - FDA
Publisher:
US Food and Drug Administration
Publication date:
09 January 2020

Abstract

Approval was based on results from the Phase 1 Navigator trial (n=43); patients had an overall response rate of 84% (95% CI: 69% to 93%), and median duration of response was not reached.